Management of Macular Degeneration
For elderly patients with macular degeneration, management depends critically on the form: wet AMD requires immediate intravitreal anti-VEGF therapy (aflibercept, ranibizumab, or bevacizumab) with initial monthly injections, while dry AMD should be treated with AREDS/AREDS2 supplementation to slow progression, and if geographic atrophy develops, consider FDA-approved pegcetacoplan or avacincaptad pegol 1, 2.
Initial Assessment and Risk Stratification
When evaluating an elderly patient with suspected AMD, perform:
- Distance visual acuity with correction
- Amsler grid testing to detect metamorphopsia
- Stereoscopic biomicroscopic fundus examination
- OCT imaging to differentiate dry from wet AMD and detect fluid 1
The distinction between dry and wet AMD is critical as it completely changes management. Wet AMD presents with subretinal or intraretinal fluid on OCT, while dry AMD shows drusen accumulation and may progress to geographic atrophy 3.
Dry (Non-Neovascular) AMD Management
AREDS/AREDS2 Supplementation
All patients with intermediate or advanced dry AMD in one eye should receive AREDS/AREDS2 supplementation, which reduces the risk of progression to advanced AMD by up to 36% over 10 years 1. The formulation includes high-dose antioxidant vitamins and minerals, though patients should have this reviewed by their primary care physician due to potential adverse effects including increased genitourinary conditions requiring hospitalization 1.
Geographic Atrophy Treatment
For the first time in 2023, two FDA-approved treatments became available for geographic atrophy: pegcetacoplan and avacincaptad pegol 2, 4. These complement pathway inhibitors have shown phase 3 evidence of reducing geographic atrophy growth 5, 2. This represents a major breakthrough as no treatment existed prior to August 2023 2.
Follow-up Protocol for Dry AMD
- Monitor for metamorphopsia and decreased vision at each visit
- Amsler grid self-monitoring at home
- Examine every 6-12 months for high-risk patients (advanced AMD in one eye with large drusen and RPE changes in fellow eye)
- Counsel on smoking cessation as smoking is a modifiable risk factor 1
Wet (Neovascular) AMD Management
Anti-VEGF Therapy: The Standard of Care
Initiate intravitreal anti-VEGF therapy immediately upon diagnosis with one of three agents: aflibercept, ranibizumab, or bevacizumab 1. These agents stop abnormal blood vessel growth and can improve vision if started early, though they cannot repair existing damage 3.
Treatment Protocol
Loading phase:
- Three initial injections at 4-week intervals 1
Maintenance phase options: After loading, three protocols exist 1:
Aflibercept every 8 weeks (preferred for many patients as it has comparable efficacy to monthly dosing after the loading phase) 1
Treat-and-extend protocol (based on treatment response, extending intervals when no fluid present)
PRN (as-needed) protocol (treat only when subretinal or intraretinal fluid detected)
A minority of retina specialists continue monthly injections, but this is not the standard approach 1.
Monitoring During Treatment
- OCT at each visit to detect subretinal or intraretinal fluid
- Fluorescein angiography and OCTA when clinically indicated for disease activity 1
- Instruct patients to report immediately: symptoms of endophthalmitis, retinal detachment, or decreased vision 1
Critical Pitfalls to Avoid
Do not delay anti-VEGF treatment in wet AMD - every week matters for visual outcomes. The earlier treatment begins, the better the visual prognosis 3.
Do not assume dry AMD requires no treatment - AREDS/AREDS2 supplementation is evidence-based and should be prescribed for intermediate and advanced disease 1. Additionally, with geographic atrophy, FDA-approved complement inhibitors are now available 2.
Do not forget the fellow eye - patients with unilateral wet AMD have high risk of developing CNV in the fellow eye. They require regular monitoring even without symptoms 1.
Review AREDS supplementation with primary care - the high doses can cause adverse effects, particularly genitourinary complications requiring hospitalization 1.
Algorithmic Approach Summary
Step 1: Confirm AMD type with OCT
- Fluid present → Wet AMD → Immediate anti-VEGF therapy
- Drusen/GA without fluid → Dry AMD → AREDS supplementation
Step 2: For wet AMD
- Start loading: 3 monthly injections
- Transition to maintenance (aflibercept q8 weeks or treat-and-extend)
- Monitor with OCT at each visit
Step 3: For dry AMD
- Prescribe AREDS/AREDS2 supplements
- If geographic atrophy: consider pegcetacoplan or avacincaptad
- Monitor every 6-12 months if high risk
- Teach Amsler grid self-monitoring
Step 4: Address modifiable risk factors
- Smoking cessation counseling
- Regular exercise and nutritious diet 3